Cardiovascular, kidney, and metabolic diseases are pathophysiologically interconnected, generally forming a serious problem for health care worldwide, associated with a significant increase in morbidity and mortality. In 2023, the American Heart Association presented the cardiovascular-kidney-metabolic syndrome (CKMS), in which dysfunction of one organ leads to progressive deterioration of the condition of others, proposed a classification and an integrated approach to the management of patients with this complex pathology. In recent years, the arsenal of drugs for the treatment of patients with CKMS has significantly expanded due to successful studies of several drugs with different mechanisms of action and approved indications for use. The review summarizes data from new literature sources, briefly describes the pathophysiology, classification, and effective methods of treatment of CKMS at all stages of its development. Patient-oriented modern medical care can improve the quality of life and prognosis in CKMS.
S. G. Кanorskiy (Sat,) studied this question.